SCHEMBL2294071

SCHEMBL2294071

O=C(Nc1ccc(Cl)cc1)ON=C1CCN(S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.51
RAB9A P51151 1/20 0.51
GAA P10253 3/20 0.50
EPHX2 P34913 2/20 0.47
LMNA P02545 4/20 0.47
KMT2A Q03164 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 1/20 0.47
MEN1 O00255 1/20 0.46
TRPV4 Q9HBA0 1/20 0.45
CYP2C9 P11712 1/20 0.44
HTT P42858 1/20 0.44
POLB P06746 1/20 0.44
RORC P51449 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CNR1 P21554 1/20 0.44
SLC20A2 Q08357 1/20 0.44
SLC20A1 Q8WUM9 1/20 0.44
ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2292379 0.92 TSHR (0.50) ALDH1A1GAAEPHX2LMNAKMT2A
SCHEMBL2291074 0.92 LMNA (0.53) ALDH1A1RAB9AGAAEPHX2LMNA
SCHEMBL2296034 0.89 KMT2A (0.51) ALDH1A1GAAEPHX2LMNAKMT2A
SCHEMBL2289836 0.89 EPHX2 (0.47) ALDH1A1GAAEPHX2LMNAKMT2A
SCHEMBL2294491 0.88 EPHX2 (0.45) ALDH1A1GAAEPHX2LMNAKMT2A
SCHEMBL2292202 0.87 MEN1 (0.50) ALDH1A1EPHX2LMNAKMT2ASMN1; SMN2
SCHEMBL2292819 0.86 LMNA (0.55) ALDH1A1GAAEPHX2LMNAKMT2A
SCHEMBL2296051 0.85 PKM (0.52) ALDH1A1RAB9AGAAEPHX2LMNA
SCHEMBL2295386 0.85 KMT2A (0.51) ALDH1A1LMNAKMT2AMAPTMEN1
SCHEMBL2292594 0.83 ALDH1A1 (0.52) ALDH1A1GAALMNACYP2C9HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S ALDH1A1 1349/4885RAB9A 2436/4885GAA 3413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.